Poster on Moditope to be presented at AACR

RNS Number : 4991K

Scancell Holdings Plc

17 April 2015

 



17 April 2015

Scancell Holdings Plc

 Moditope® citrullinated peptides destroy tumours and extend survival

Poster to be presented at American Association for Cancer Research Annual Meeting

Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, today announces that a poster exemplifying the Company's Moditope® immunotherapy platform has been accepted for presentation at the American Association for Cancer Research Annual Meeting (AACR) in Philadelphia, Pennsylvania, 18-22 April 2015.

The AACR Annual Meeting highlights the latest, most exciting discoveries in every area of cancer research and provides a unique opportunity for investigators from all over the world to meet, interact, and share their insights. This year's meeting theme - "Bringing Cancer Discoveries to Patients" - underscores the vital and inextricable link between discovery and treatment, and it reinforces the fact that research underpins all the progress being made in the field toward cancer cures.

The title, timing and location of the poster presentation is as follows:

Abstract:	1348
Title:	CD4 T cells targeting citrullinated vimentin reject advanced tumors
Day/Date:	Monday 20 April 2015
Session Time:	8:00am to 12:00pm EDT
Location:	Section 13, Poster Board Number 18

The presentation abstract can be accessed through the AACR website:

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0cf4d7d6-5069-4032-996a-84e0ceb978ef&cKey=c7d3f1c7-31d2-4063-b18e-40db764186e6&mKey=%7b19573A54-AE8F-4E00-9C23-BD6D62268424%7d 

For Further Information:

Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc Scancell Holdings Plc	+ 44 (0) 20 3727 1000
Robert Naylor/Maisie Atkinson	Panmure Gordon	+ 44 (0) 20 7886 2500
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

NRADQLFFEZFBBBL